

DISCUSSION OF THE AMENDMENT

Claim 1 has been amended by changing the lower value for “n” to --10--, as supported by original Claim 2, and by limiting it to the elected subject matter. Claims 3-5 have been canceled. Claim 7 has been amended using conventional method of treatment language. Claim 8 has been amended to depend on Claim 6.. Where applicable, the term “derivative” has been replaced with --compound--, and the term “general” has been deleted. The term “containing” has been changed to --of--.

New Claims 9-19 have been added. Claims 9-17 are drawn to variations embodiments of the elected invention, as supported by the various examples. Claim 18 is of even scope to original Claim 1, except that the lower value for “n” is --10--. Claim 19 is identical to Claim 18, except that it limits the “other” groups of the R^1 , R^2 , R^3 , and R^4 to hydrogen or an alkyl group of 1 to 6 carbon atoms.

The Abstract has been amended into one paragraph.

No new matter is believed to have been added by the above amendment. Claims 1, 2 and 6-19 are now pending in the application. Of these claims, Claims 7 and 8 stand withdrawn, but are rejoinable.

REMARKS

Applicants thank the Examiner and the Examiner's supervisor for the courtesy extended to Applicants' attorney during the interview held June 7, 2007, in the above-identified application. During the interview, Applicants' attorney explained the presently-claimed invention and why it is patentable over the applied prior art, and discussed other issues raised in the Office Action. The discussion is summarized and expanded upon below.

The rejections of Claims 1 and 3-6 under 35 U.S.C. § 102(b) as anticipated by each of:

Chem. Pharm. Bull. 49(5), 2001, p. 563-571 (Kamiya et al);

US 3,974,179 (Demerson et al);

Journal of the American Pharmaceutical Association, Scientific Edition, vol. 32, 1943, p. 83-89 (Murphy et al);

US 3,996,241 (Heerdt et al);

US 2002/0058648 (Hammerly); and

US 5,703,070 (Lavielle et al)¹,

are respectfully traversed.

All of the above-amended claims require that "n" be at least 10. None of the applied prior art discloses or suggests the presently-claimed subject matter. Accordingly, it is respectfully requested that these rejections be withdrawn.

The rejection of Claims 1-6 under 35 U.S.C. § 103(a) as unpatentable over Lavielle et al, is respectfully traversed. In Lavielle et al, particularly the compounds of formula (II) (column 3, line 28ff), wherein R₁ is an alkoxy, X is N, Y is CH, and R₂ is hydrogen, as defined in formula (I) (column 2, line 28ff), "n" varies from 1 to 6. There is no disclosure or

¹ While the EP equivalent of Lavielle et al is of record, the US equivalent has not been made of record on the appropriate form. The Examiner is respectfully requested to make the US Lavielle et al of record in the next Office communication.

suggestion in Lavielle et al to extend n to higher numbers, such as 10. Applicants acknowledge the Examiner's indication during the above-referenced interview, that the above argument is, in effect, correct. Accordingly, it is respectfully requested that this rejection be withdrawn.

The rejection of Claims 4 and 5 under 35 U.S.C. § 112, first paragraph, as failing to comply with the enablement requirement, is respectfully traversed. Indeed, the rejection is now moot in view of the above-discussed amendment. Accordingly, it is respectfully requested that the rejection be withdrawn.

The rejection of Claims 1-3, 5 and 6 under 35 U.S.C. § 112, second paragraph, is respectfully traversed. Indeed, the rejection would now appear to be moot in view of the above-discussed amendment. With regard to the term "containing" and its use to characterize an amount of carbon atoms in a particular group, the term "containing" has been notoriously so used, and to Applicants' attorney's knowledge, as explained during the interview, has never been interpreted to mean when used, for example, in a term such as "an alkoxy group containing 1 to 20 carbon atoms," as inclusive of alkoxy groups containing more than 20 carbon atoms. Nevertheless, this rejection should be moot, in view of the change of "containing" to --of--.

For all the above reasons, it is respectfully requested that this rejection be withdrawn.

The objection to Claim 4 is respectfully traversed. Indeed, the objection is now moot in view of the above-discussed amendment. Accordingly, it is respectfully requested that the objection be withdrawn.

The objection to Claims 1-6 as containing or dependent on subject matter withdrawn from consideration is respectfully traversed. All but new Claims 18 and 19 are drawn to elected subject matter. No lack of unity of invention has been shown for the subject matter of Claim 18. In addition, and as Applicants' attorney requested during the interview, the

restriction requirement should be reconsidered and Claims 18 and 19 should be examined, in view of the above-discussed amendment. Accordingly, it is respectfully requested that the objection be withdrawn.


The objection to the Abstract of the Disclosure as containing more than one paragraph is now moot in view of the above-discussed amendment. Accordingly, it is respectfully requested that the objection be withdrawn.

All of the presently-pending claims in this application are now believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon



Harris A. Pitlick

Registration No. 38,779

Customer Number

22850

Tel: (703) 413-3000

Fax: (703) 413 -2220

(OSMMN 06/04)

NFO:HAP\la